71 Results for "

p110α

" in MedChemExpress (MCE) Product Catalog:
Products (71)

71 Results for "p110α" in MCE Product Catalog:

  • Isoforms Recommended:
1199
1199 Publications Verification
Cat. No.: HY-10108A
CAS No.: 934389-88-5
Purity:  99.93%
Research Areas:  

Cancer

LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC50 values of 0.5, 0.57, and 0.97 μM for P110α, P110δ and P110β, respectively. LY294002 hydrochloride also inhibits CK2 with an IC50 of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research .
loading...
    loading...
132
132 Cited Publications
Cat. No.: HY-15244
CAS No.: 1217486-61-7
Purity:  99.88%
Synonyms: BYL-719
Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .
loading...
    loading...
132
132 Cited Publications
Cat. No.: HY-15244A
CAS No.: 1584128-91-5
Synonyms: BYL-719 hydrochloride
Alpelisib (BYL-719) hydrochloride is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib hydrochloride also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib hydrochloride not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib hydrochloride can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .
loading...
    loading...
90
90 Cited Publications
Cat. No.: HY-70063
CAS No.: 944396-07-0
Synonyms: BKM120; NVP-BKM120
Target:  

PI3K Apoptosis

Research Areas:  

Cancer

Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with blood-brain barrier permeability. Buparlisib has IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively .
loading...
    loading...
90
90 Cited Publications
Cat. No.: HY-15180
CAS No.: 1312445-63-8
Purity:  99.88%
Synonyms: BKM120 Hydrochloride; NVP-BKM120 Hydrochloride
Buparlisib Hydrochloride (BKM120 Hydrochloride) is a CNS-penetrant pan-class I PI3K inhibitor, with IC50 of 52 nM/166 nM/116 nM/262 nM for p110α/p110β/p110δ/p110γ, respectively.
loading...
    loading...
71
71 Cited Publications
Cat. No.: HY-50673
CAS No.: 915019-65-7
Synonyms: BEZ235; NVP-BEZ235
Target:  

PI3K mTOR Autophagy

Research Areas:  

Cancer

Dactolisib (BEZ235) is an orally active and dual pan-class I PI3K and mTOR kinase inhibitor with IC50s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for p110α/p110γ/p110δ/p110β and mTOR, respectively. Dactolisib (BEZ235) inhibits both mTORC1 and mTORC2.
loading...
    loading...
67
67 Cited Publications
Cat. No.: HY-50673A
CAS No.: 2319647-83-9
Synonyms: BEZ235 hydrochloride; NVP-BEZ235 hydrochloride
Target:  

PI3K mTOR Autophagy

Research Areas:  

Cancer

Dactolisib (BEZ235) hydrochloride is an orally active, dual pan-class I PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR with IC50 of 4 nM/5 nM/7 nM/75 nM and 20.7 nM, respectively. Dactolisib hydrochloride (BEZ235) inhibits mTORC1 and mTORC2 .
loading...
    loading...
33
33 Cited Publications
Cat. No.: HY-10115
CAS No.: 371935-74-9
Purity:  99.82%
Research Areas:  

Cancer

PI-103 is a potent PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK with an IC50 of 2 nM. PI-103 induces autophagy .
loading...
    loading...
33
33 Cited Publications
Cat. No.: HY-10115A
CAS No.: 371935-79-4
Purity:  98.55%
Research Areas:  

Cancer

PI-103 Hydrochloride is a dual PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 Hydrochloride also inhibits DNA-PK with an IC50 of 2 nM. PI-103 Hydrochloride induces autophagy .
loading...
    loading...
20
20 Cited Publications
Cat. No.: HY-10297
CAS No.: 1086062-66-9
Purity:  99.94%
Synonyms: GSK2126458; GSK458
Target:  

PI3K mTOR Autophagy

Research Areas:  

Cancer

Omipalisib (GSK2126458) is an orally active and highly selective inhibitor of PI3K with Kis of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. Omipalisib has anti-cancer activity .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-17044
CAS No.: 1201438-56-3
Synonyms: IPI-145; INK1197
Target:  

PI3K

Research Areas:  

Cancer

Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-13228
CAS No.: 371942-69-7
Purity:  98.05%
Research Areas:  

Infection Cancer

YM-201636 is a potent and selective PIKfyve inhibitor with an IC50 of 33 nM. YM-201636 also inhibits p110α with an IC50 of 3.3 μM. YM-201636 inhibits retroviral replication.
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-15245
CAS No.: 1372540-25-4
Purity:  99.59%
Target:  

PI3K

Research Areas:  

Cancer

GSK2636771 is a potent, selective and orally bioavailable inhibitor of PI3Kβ with a Ki of 0.89 nM and an IC50 of 5.2 nM, showing 900-fold selectivity over p110α and p110γ, and 10-fold selectivity over p110δ isoforms.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-12030
CAS No.: 677338-12-4
Purity:  99.61%
Target:  

PI3K DNA-PK

Research Areas:  

Cancer

PIK-90 is a DNA-PK and PI3K inhibitor, which inhibits p110α, p110γ and DNA-PK with IC50s of 11, 18 and 13 nM, respectively.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-13281
CAS No.: 372196-77-5
Purity:  99.72%
Target:  

DNA-PK PI3K Apoptosis

Research Areas:  

Cancer

PIK-75 hydrochloride is a reversible DNA-PK and p110α-selective inhibitor, which inhibits DNA-PK, p110α and p110γ with IC50s of 2, 5.8 and 76 nM, respectively. PIK-75 hydrochloride inhibits p110α >200-fold more potently than p110β (IC50=1.3 μM) . PIK-75 hydrochloride induces apoptosis .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-15900
CAS No.: 934493-76-2
Purity:  99.82%
Synonyms: XL765; SAR245409
Target:  

PI3K mTOR

Research Areas:  

Cancer

Voxtalisib (XL765) is a potent PI3K inhibitor, which has a similar activity toward class I PI3K (IC50s=39, 113, 9 and 43?nM for p110α, p110β, p110γ and p110δ, respectively), also inhibits DNA-PK (IC50=150?nM) and mTOR (IC50=157?nM). Voxtalisib (XL765) inhibits mTORC1 and mTORC2 with IC50s of 160 and 910 nM, respectively.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-107834
CAS No.: 372196-67-3
Purity:  99.94%
Target:  

DNA-PK PI3K Apoptosis

Research Areas:  

Cancer

PIK-75 is a reversible DNA-PK and p110α-selective inhibitor, which inhibits DNA-PK, p110α and p110γ with IC50s of 2, 5.8 and 76 nM, respectively. PIK-75 inhibits p110α >200-fold more potently than p110β (IC50=1.3 μM) . PIK-75 induces apoptosis .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-12235
CAS No.: 955977-50-1
Purity:  98.97%
Target:  

PI3K

Research Areas:  

Inflammation/Immunology Cancer

PI-3065 is a potent inhibitor of PI3K p110δ, with IC50 and Ki values of 5 nM and 1.5 nM, and exhibits less potent activity against p110α, p110β, p110γ with IC50s of 910, 600, >10000 nM.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-13261
CAS No.: 1166227-08-2
Purity:  99.73%
Target:  

PI3K

Research Areas:  

Cancer

A66 is a highly specific and selective p110α inhibitor with an IC50 of 32 nM.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108606
CAS No.: 942289-87-4
Purity:  99.62%
Target:  

PI3K Casein Kinase

Research Areas:  

Cancer

PI-828 is a dual PI3K and casein kinase 2 (CK2) inhibitor with IC50s of 173 nM, 149 nM, and 1127 nM for p110α, CK2, and CK2α2 in lipid kinase assay, respectively .
loading...
    loading...